rss
J Clin Pathol doi:10.1136/jcp.2007.052431

FOXA1 expression in breast cancer is associated with Luminal subtype and good prognosis.

  1. Mangesh A Thorat (thoratmangesh{at}gmail.com)
  1. Dept. of Pathology & Laboratory Medicine, IU School of Medicine, United States
    1. Caterina Marchio (caterina.marchio{at}icr.ac.uk)
    1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, United Kingdom
      1. Akira Morimiya (amorimiy{at}iupui.edu)
      1. Dept. of Pathology & Laboratory Medicine, IU School of Medicine, United States
        1. Kay Savage (kay.savage{at}icr.ac.uk)
        1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, United Kingdom
          1. Harikrishna Nakshatri (hnakshat{at}iupui.edu)
          1. Dept. of Surgery, IU School of Medicine, United States
            1. Jorge S Reis-Filho (jorge.reis-filho{at}icr.ac.uk)
            1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, United Kingdom
              1. Sunil Badve (sbadve{at}iupui.edu)
              1. Dept. of Pathology & Laboratory Medicine, IU School of Medicine, United States
                • Published Online First 23 November 2007

                Abstract

                Purpose: FOXA1 is a forkhead family transcription factor expressed in breast cancer cells. It is essential for optimal expression of ~50% ofƒnER-related genes. We explored FOXA1 relationship with luminal and basal breast cancer subtypes, proliferation markers and survival in breast cancer patients who had received similar treatment. Materials and Methods: A tissue microarray comprising tumours from 245 invasive breast cancer patients with 67 months of median follow-up was analyzed for FOXA1 expression by immunohistochemistry. Interpretable FOXA1 expression, obtained in 184 patients, was analyzed along with other variables like tumour grade, size, nodal status, ER, PR, HER2/neu, proliferation and basal markers. Results: FOXA1 expression (score >3) was seen in 139/184 breast cancers. It correlated positively with ERƒÑ (p<0.0001), PR (p<0.0001), and luminal subtype (p<0.0001); negatively with basal subtype (p<0.0001), proliferation markers and high histological grade (p=0.0327). Univariate analysis showed nodal status, tumour grade, ER, PR, FOXA1, basal markers and p53 as significant predictors of overall survival (OS). Multivariate analysis showed only nodal status (p=0.0006) and ER (p=0.0017) to be the significant predictors of OS. In luminal subtype patient subgroup, FOXA1 expression was associated with better survival (p=0.0284) on univariate analysis. Conclusion: Based on this study in patients treated surgery followed by adjuvant anthracycline-based chemotherapy, FOXA1 expression is associated with good prognosis. It correlates with luminal subtype breast cancer, and could possibly serve as a clinical marker for luminal subtype-A. Prognostic ability of FOXA1 in these low-risk breast cancers may prove to be useful in treatment decision making.

                Latest from JCP Education

                Latest from JCP Education

                Register for free content


                Free sample
                This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
                View free sample issue >>

                Free archive
                The full back archive is now available for JCP. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
                Register to access the free archive >>

                Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

              1. Latest Pathology jobs

                Latest Pathology jobs